Lexeo Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · New York, NY
LXEO chart
What traders are saying about $LXEO
Latest postsLexeo Therapeutics, Inc. news
- Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
marketbeat.com ·
- Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - Slideshow (NASDAQ:LXEO) 2026-10-24
Seeking Alpha ·
- Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
marketbeat.com ·
- Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
Yahoo Finance ·
- Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
Yahoo Finance ·
- Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Yahoo Finance ·
- Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
Yahoo Finance ·
- Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Yahoo Finance ·
- Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
Yahoo Finance ·
- Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
Yahoo Finance ·
- Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Yahoo Finance ·
- Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
Yahoo Finance ·
Lexeo Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | $654,000 |
| Net income | -$100.0M | -$98.3M | -$66.4M | -$59.3M |
| Diluted EPS | $-1.86 | $-3.09 | $-12.40 | $-36.36 |
| Total assets (year end) | $268.7M | $146.9M | $139.8M | $97.1M |
| Cash and equivalents (year end) | $63.0M | $35.0M | $121.5M | $77.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Lexeo Therapeutics, Inc.
- Ticker
- LXEO (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- SEC CIK
- 1907108
Frequently asked questions
What exchange is Lexeo Therapeutics, Inc. listed on?
Lexeo Therapeutics, Inc. trades on the Nasdaq under the ticker symbol LXEO.
What industry is Lexeo Therapeutics, Inc. in?
Lexeo Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Lexeo Therapeutics, Inc. headquartered?
Lexeo Therapeutics, Inc.'s business address on file with the SEC is in New York, NY.
When does Lexeo Therapeutics, Inc.'s fiscal year end?
Lexeo Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Lexeo Therapeutics, Inc. report?
Lexeo Therapeutics, Inc. reported $654,000 in revenue for calendar year 2022, according to its SEC filings.